1935 ⎘
Rearing or breeding animals, not otherwise provided for; New breeds of animals; New breeds of vertebrates; Genetically modified vertebrates, e.g. transgenic Knockout animals
TAAR1 knock out animal
#1202Inhibitor of differentiation knockout mammals and methods of use thereof
#1203Methods of generating knock-out rodents
#1204Compositions and methods of using angiopoietin-like 4 protein
#1205Inactive Ca/calmodulin-dependent protein kinase IIα knockin animal and knockin cell of the same
#1206Method of treatment and prophylaxis
#1207Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse
#1208Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse
#1209Goodpasture's syndrome model mouse
#1210Methods of modulating bone growth, bone remodeling and adiposity
#1211Uses for Eph receptor antagonists and agonists
#1212Transgenic non-human Act1-deficient mammals and uses thereof
#1213Proliferator-Activated Receptor Disruptions, Compositions and Methods Relating Thereto
#1214Nonhuman model animal suffering from Guillain-Barré syndrome and/or fisher syndrome
#1215Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation
#1216Lysosomal proteins produced in the milk of transgenic animals
#1217Mo54 Disruptions, Compositions and Methods Related Thereto
#1218WIP, a WASP-associated protein
#1219Novel haemopoietin receptor and genetic sequences encoding same
#1220Anti-viral activity of cathelicidin peptides
#1221SCREENING SYSTEMS AND METHODS FOR IDENTIFYING MODULATORS OF XENOBIOTICMETABOLISM
#1222CD9/CD81 double-deficient non-human animal
#1223Artery-and vein-specific proteins and uses therefor
#1224Mediators of epithelial adhesion and their role in cancer and skin disorders
#1225Methods for treating demyelination disorders
#1226Functional characterization of myo-inositol monophosphatase
#1227Compositions and Methods for Making Embryonic Stem Cells
#1228Cathepsin G (CTSG) Disruptions, Compositions and Methods Relating Thereto
#1229Screening method with the use of TBK1 knockout mouse
#1230Gab2 (p97) gene and methods of use thereof
#1231Compositions and methods for treatment of autoimmune and related diseases
#1232Animals with reduced body fat and increased bone density
#1233Cathepsin-associated genetically modified nonhuman mammal
#1234Site-specific gene conversion promoter and gene therapeutic
#1235Transgenic Mice Containing Kir3.3 Potassium Channel Gene Disruptions
#1236Methods of treatment of feeding disorders or disorders of glucose uptake and for modifying metabolism and identifying therapeutic reagents therefor
#1237Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
#1238CCR6 chemokine receptor disruptions, compositions and methods relating thereto
#1239Slim compositions and methods of use thereof
#1240Receptor
#1241Chimeric mouse with regulated bradeion gene expression
#1242Method to enrich for α(1,3)-galactosyltransferase null pig cells
#1243Inducible site-directed mutagenesis through conditional gene rescue
#1244Methods for treatment of pain
#1245T cell regulation
#1246Protein Arginine N-Methyltransferase 2 (PRMT-2)
#1247Genetically modified non-human mammals and cells
#1248Transgenic mammal carrying GANP gene transferred thereinto and utilization thereof
#1249Modulation of angiogenesis
#1250Sequences used to identify if a female mammal comprises a mutation in the alpha-fetoprotein sequence(S) or a partial or total deletion of the alpha-fetoprotein sequence(S)
#1251Gene-targeted animal model of apolipoprotein E4 domain interaction and uses thereof
#1252Transgenic mice containing mGluR7 metabotropic glutamate receptor gene disruptions
#1253Transgenic mice containing lymphoid-specific GPCR gene disruptions
#1254Tr2, tr4, tr2/tr4 double knockouts and uses thereof
#1255Method for preparing anti-MIF antibodies
#1256Transgenic mice containing SOCS-5 cytokine signalling suppressor gene disruptions
#1257Transgenic mice containing channel activating protease 1 (CAP1) gene disruptions
#1258Transgenic mice containing deubiquitinated enzyme gene disruptions
#1259Transgenic mice containing MSK2 serine/threonine kinase gene disruptions
#1260Transgenic mice containing adrenocorticotropin hormone receptor gene disruptions
#1261Transgenic mice containing melanocyte stimulating hormone receptor gene disruptions
#1262Protecting cell therapy for neurological disorders including Parkinson's disease
#1263Transgenic mice containing lumulus clotting factor protease-like gene disruptions
#1264ADAM-like protease disruptions, compositions and methods related thereto
#1265Mammalian grainyhead transcription factors
#1266Artificial human chromosome containing human antibody a light chain gene
#1267Transgenic mice containing, cGMP phosphodiesterase gene disruptions
#1268GNG4 gene disruptions, compositions and methods related thereto
#1269Method of screening antiobesity agents and animal model of obesity
#1270Transgenic mice containing CX2 gene disruptions
#1271Methods for preventing or treating a condition or a disease associated with angiogenesis
#1272TRP6 calcium channel disruptions, compositions and methods related thereto
#1273Transgenic mice containing sulfotransferase gene disruptions
#1274Compositions and methods for treating female fertility
#1275Transgenic mice containing anaphylatoxin C3a gene disruptions
#1276OGR1 gene disruptions, compositions and methods relating thereto
#1277Transgenic mice containing tryptase gene disruptions
#1278Transgenic mice containing chordin gene disruptions
#1279Selective inhibition of rock1 in cardiac therapy
#1280Method of detecting bone paget's disease
#1281Transgenic mice containing retinoid X receptor interacting protein gene disruptions
#1282Protein tyrosine phosphatase RPTP-beta disruptions, compositions and methods relating thereto
#1283Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
#1284Ungulates with genetically modified immune systems
#1285V1a arginine vasopressin receptor disruptions, compositions and methods relating thereto
#1286Assay methods for identifying RE2-like antagonists, methods of use, and non-human transgenic animals
#1287Knockout mice and their use
#1288Methods of identifying modulators of NMUR2-mediated activity
#1289Methods for increasing the diversity of monoclonal antibodies produced against an antigen
#1290Assay methods for identifying modulators of OPSDL3 and transgenic knockouts
#1291Expression of xenogenous (human) immunoglobulins in cloned, transgenic ungulates
#1292Expression of xenogenous (human) immunoglobulins in cloned, transgenic ungulates
#1293CYT28 serpentine receptor disruptions, compositions and methods relating thereto
#1294Delta opioid receptor disruptions, compositions and methods related thereto
#1295Transgenic mice containing glucocorticoid-induced receptor gene disruptions
#1296Calpain large subunit (n-CL4) cysteine protease gene disruptions, and compositions and methods related thereto
#1297Transgenic mice containing NTTP1 phosphatase gene disruptions
#1298Transgenic mice containing beta3GalT2 gene disruptions
#1299Transgenic mice containing TMEM3 beta-1,3-N-acetylglucosaminyltransferase gene disruptions
#1300Transgenic mice containing CLCN4 chloride ion channel gene disruptions
#1301Compositions and methods of using angiopoietin-like 4 protein antibody
#1302Method of treatment and prophylaxis
#1303Method of treatment and an animal model useful for same
#1304Transgenic mice containing Kir5.1 inwardly rectifying potassium channel gene disruptions
#1305Modulation of type IIß phosphoinositide phosphate kinase
#1306Isolated clk-1 -/- cells from clk-1 heterozygous animals and their use in treating oxidative stress disorders
#1307Method for generating an animal homozygous for a genetic modification
#1308Transgenic mice containing GPCR-like gene disruptions
#1309Transgenic mice containing PAFR gene disruptions
#1310Muir-Torre-like syndrome in Fhit deficient mice
#1311Prevention of primary Sjogren's Syndrome by ICA69 deficiency
#1312Animal model for studying hormone signalling and method of modulating the signalling
#1313Conditional disruption of dicer1 in cell lines and non-human mammals
#1314Murine Pten null prostate cancer model
#1315Histamine receptor H3 modified transgenic mice
#1316Adiponectin-knoucout nonhuman animal
#1317Melusin a muscle specific protein, as a drug target for prevention and treatment of heart failure
#1318Methods of promoting neurite outgrowth with soluble TAJ polypeptides
#1319Carbohydrate determinant selection system for homologous recombination
#1320Cranial and vertebral defects associated with loss-of-function of Nell
#1321Modification of sugar metabolic processes in transgenic cells, tissues and animals
#1322Methods and compositions for cell activation
#1323Transgenic TIEG non-human animals
#1324Transgenic mice containing chemokine receptor 9A gene disruptions
#1325Nessie nucleic acids, polypeptides and mutations, and methods of use thereof
#1326Transgenic animals and uses thereof
#1327Antagonizing interleukin-21 receptor activity
#1328Secreted protein associated with depression, compositions and methods of use thereof
#1329Transgenic transchromosomal rodents for making human antibodies
#1330Artery- and vein-specific proteins and uses therefor
#1331Antibodies to the extracellular domain of human polypeptide and methods of making said antibodies
#1332JNK3 modulators and methods of use
#1333Transgenic mouse expressing human FcRn protein
#1334Mutant mice comprising a mutated type II procollagen alpha-1
#1335GRP94-based compositions and methods of use thereof
#1336Lysyl oxidase-like 1 (LOXL1) and elastogenesis
#1337Transgenic non-human animals for producing heterologous and chimeric antibodies
#1338Transgenic transchromosomal rodents for making human antibodies
#1339Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
#1340Methods and products related to the production of inner ear hair cells
#1341Noc2 knockout mouse
#1342Human artificial chromosome containing human antibody λ light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission
#1343Transgenic non-human animals for producing chimeric antibodies
#1344GPR54 knock-out mammals and screening methods using them
#1345Transgenic non-human animals for producing heterologous and chimeric antibodies
#1346Methods of inhibiting tumor cell proliferation
#1347Endophilin III gene disruptions, compositions and methods related thereto
#1348Vectors having both isoforms of beta-hexosaminidase
#1349Methods and agents for maintaining muscle mass and for preventing muscle atrophy and biomarkers for monitoring same
#1350Therapeutic and diagnostic proteins comprising a SOCS box
#1351Methods for treating conditions associated with MASP-2 dependent complement activation
#1352CXCR6 chemokine receptor gene disruptions, and compositions and methods related thereto
#1353Cre-lox based method for conditional RNA interference
#1354CARD-4 molecules and uses thereof
#1355Method for preventing or treating cardiac hypertrophy
#1356Vitamin K epoxide recycling polypeptide VKORC1, a therapeutic target of coumarin and their derivatives
#1357Transgenic mice containing brain-specific membrane-anchored protein gene disruptions
#1358Transgenic mouse with a targeted deletion of Elovl4 gene
#1359Antisense composition and method for treating cancer
#1360Anti-neovasculature preparations for cancer
#1361Tissue products derived from porcine animals lacking any expression of functional alpha 1,3 galactosyltransferase
#1362Nonhuman model animal nonresponsive to endotoxin and lipoprotein or lipopeptide
#1363Agouti-related protein deficient cells, non-human transgenic animals and methods of selecting compounds which regulate energy metabolism
#1364Transgenic non-human animals expressing a truncated activin type II receptor
#1365Mice lacking alpha 1G showing enhanced novelty-seeking and alcohol preference and therapeutic methods for mood disorders by modulating alpha 1G T-type calcium channels
#1366ACE2 activation for treatment of heart, lung and kidney disease and hypertension
#1367Methods for use of TSLP and agonists and antagonists thereof
#1368Method of screening a compound for anxiolytic activity in an apolipoprotein E knockout animal
#1369IEX-1 knockout animals
#1370Nonhuman model animal unresponsive to immunopotentiating synthetic compound
#1371Spatiotemporally controlled adult somatic mutagenesis system
#1372Inducible heart attack animal model
#1373Porcine CMP-N-Acetylneuraminic acid hydroxylase gene
#1374Pancreas-specific proteins
#1375Prion-free transgenic ungulates
#1376Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species
#1377Modulation of an innate immune response by altering TRIAL-R signaling
#1378In vitro uptake of SPAM 1 (PH-20) by mammalian sperm
#1379Methods of preforming homologous recombination based modification of nucleic acids in recombination deficient cells and use of the modified nucleic acid products thereof
#1380Non-human animal model of oligodendrocyte developmental disorder
#1381Methods and compositions for the treatment of obesity
#1382Human schizophrenia gene
#1383Use of agonists and antagonists of IL-23 in the treatment of viral infection
#1384Artery- and vein-specific proteins and uses therefor
#1385SIRT6 transgenic non-human animals and assay methods
#1386Human CTLA-4 antibodies and their uses
#1387Knockin non-human animal and tissue-specific MnSOD knockout non-human animal
#1388IL-21 as a regulator of immunoglobin production
#1389Compositions and methods of modulating cholesterol metabolism
#1390Lysyl oxidase-like 1 (LOXL1) and elastogenesis
#1391Mouse exhibiting characteristics of Rothmund-Thomson syndrome and preparation method thereof
#1392Production of ungulates, preferably bovines that produce human immunoglobulins
#1393Somatic cells, germ cells and cell lines derived from a PTTG knockout rodent
#1394CCN1 transgenic animals
#1395Polynucleotides encoding growth differentiation factor-8
#1396Mouse in which genome is modified
#1397CFTR modifier genes and expressed polypeptides useful in treating cystic fibrosis and methods and products for detecting and/or identifying same
#1398Methods and compositions for preventing obesity and obesity related disorders
#1399Eosinophil-deficient transgenic animals
#1400Methods for modulating the activity of MSH-5
#1401Compositions and methods for treating female fertility
#1402Methods for treating circadian rhythm phase disturbances
#1403Knockout mouse
#1404Bispecific antibodies
#1405Adipocytes and uses thereof
#1406Non-human mutant mammals deficient in Sigma receptors and their applications
#1407Animal model for the analysis of tumor metastasis
#1408Aiolos, Helios, Daedalos and Ikaros: genes, polypeptides, regulatory elements and uses thereof
#1409Knockout mouse for the tumor suppressor gene ANX7
#1410α(1,3)-galactosyltransferase knockout swine, tissues and organs
#1411Transgenic zebrafish models for thrombosis
#1412Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
#1413Porcine invariant chain protein, full length cDNA, genomic organization, and regulatory region
#1414Transgenic RS1-/- animal and uses thereof
#1415Modulation of angiogenesis
#1416Transgenic bovines having reduced prion protein production
#1417Ant2 conditional knockout mouse and methods
#1418Nonhuman model animal of Th2-mediated hyperimmune response
#1419P2x7 receptor-deficient non-human animals and uses thereof
#14207B2 knockout transgenic animals as models of endocrine disease
#1421Methods to identify compounds useful for the treatment of proliferative and differentiative disorders
#1422Generation of xenogeneic antibodies
#1423Nonhuman model animal lacking the ability to control lymphocyte migration
#1424HBM variants that modulate bone mass and lipid levels
#1425Regulation of cardiac contractility and heart failure propensity
#1426Non-human animal model of systemic lupus erythematosus
#1427GRP94-based compositions and methods of use thereof
#1428Mouse λ light chain locus
#1429Methods and products for identifying modulators of P2X7 receptor activity, and their use in the treatment of skeletal disorders
#1430LKB1 gene knockout animals
#1431Modulation of angiogenesis
#1432Treatment of chronic human viral hepatitis
#1433Sgrf gene-modified non-human animals
#1434Phenotypic effects of ubiquinone deficiencies and methods of screening thereof
#1435Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
#1436Melanocortin-3 receptor deficient cells, non-human transgenic animals and methods of selecting compounds which regulate body weight
#1437Methods of inhibiting tumor cell proliferation
#1438Methods of modulating apoptosis by administration of relaxin agonists or antagonists
#1439GLYT1 conditional knock-out mice
#1440Compositions and methods for modulating S-nitrosoglutathione reductase
#1441Method of screening for compounds that modulate activity of a regulatory sequence of the β-2 subunit of a neuronal nicotinic acetylcholine receptor
#1442Methods for modulating hematopoiesis and vascular growth
#1443PTP4A1 as a therapeutic target for fibrotic diseases and disorders including systemic sclerosis